Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4483 Metabolic parameters and visceral adiposity index in type 1 gastric neuroendocrine tumours: A single-centre cross-sectional study

Introduction: Studies have shown that the accumulation of visceral fat and the occurrence of metabolic syndrome (MetS) lead to disruptions in immune-metabolic crosstalk, contributing to the development and progression of autoimmune diseases and well-differentiated gastric neuroendocrine tumours (gNETs).

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen R, Wang Y, Wang Y,

Keywords: Type 1 gastric neuroendocrine tumour, Metabolic Syndrome, Visceral Adiposity Index,

#4394 Application of somatostatin receptor PET/CT in assisting preoperative lymph node evaluation and surgical decision-making for duodenal and pancreatic neuroendocrine neoplasms

Introduction: Preoperative precise staging of lymph nodes is crucial for determining surgical approach and extent for duodenal and pancreatic neuroendocrine neoplasms (DP-NENs), especially for small (≤2cm) DP-NENs.

Conference:

Presenting Author:

Authors: Xianze W, Bohui Y, Wenjia Z, Wensheng L, Meixi L,

Keywords: 68Ga-SSTR PET/CT, neuroendocrine neoplasm, lymph node metastasis, surgical decision-making,

#4342 A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of unresectable, locally advanced or metastatic neuroendocrine neoplasms in China

Introduction: The incidence of NENs is on the rise. In NECs, research on surufatinib is still scarce.

Conference:

Presenting Author:

Authors: Liu S, Zhang L, Liu B, Liu Q,

Keywords: neuroendocrine neoplasm, surufatinib, neuroendocrine carcinoma, neuroendocrine tumour, real-world study,

#4148 S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multicentre phase 2 trial

Introduction: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumors (NETS) and the efficacy of existing treatments is sub-optimal.

Conference:

Presenting Author:

Authors: Chi Y, Song L, Liu W, Zhou Y, Miao Y,

Keywords: S-1, temozolomide, thalidomide, neuroendocrine tumor,

#4043 Treatments, clinicopathological characteristics and prognosis in thymic neuroendocrine tumors (TNETs): With especial reference to Temozolomide (TMZ)-based chemotherapy

Introduction: Thymic neuroendocrine tumors (TNETs) are rare but aggressive malignant neoplasms that exhibit significant heterogeneity. However, there is a paucity of comprehensive clinical studies conducted to investigate the prognosis of TNETs.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Cui L, Chen X, Zheng J,

Keywords: thymic neuroendocrine tumor, treatment, prognosis, temozolomide,